World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
34300
World Ranking
11662
National Ranking
472

Overview

Gary Remington is affiliated with the Centre for Addiction and Mental Health in Canada. Their research primarily focuses on medicine, with an emphasis on psychiatry and mental health. Within this broad domain, they have contributed extensively to subfields including psychiatry and mental health, cognitive neuroscience, molecular biology, physiology, and clinical psychology.

Their published works span several main topics, notably schizophrenia research and treatment, diet and metabolism studies, bipolar disorder and treatment, functional brain connectivity studies, tryptophan and brain disorders, advanced neuroimaging techniques and applications, and mental health and psychiatry.

Some of their recent papers include:

  • Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment (2022, Molecular Psychiatry)
  • Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis (2020, CNS Drugs)
  • Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health (2021, Schizophrenia)
  • Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series (2023, Therapeutic Advances in Psychopharmacology)
  • Pharmacological interventions for prevention of weight gain in people with schizophrenia (2022, Cochrane Database of Systematic Reviews)

Their frequent coauthors include:

  • Philip Gerretsen
  • Ariel Graff-Guerrero
  • Sri Mahavir Agarwal
  • Margaret Hahn
  • Vincenzo De Luca

Gary Remington has published extensively in several venues known for psychiatric and neuroscience research, such as:

  • Biological Psychiatry
  • Schizophrenia Bulletin
  • Schizophrenia Research
  • Schizophrenia
  • Psychiatry Research

Best Publications

  • Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

    Shitij Kapur;Robert Zipursky;Corey Jones;Gary Remington

  • A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

    Guy Chouinard;Barry Jones;Gary Remington;David Bloom

  • Serotonin-dopamine interaction and its relevance to schizophrenia

    Shitij Kapur;Gary Remington

  • Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

    Oliver D. Howes;Rob McCutcheon;Ofer Agid;Andrea De Bartolomeis

  • Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

    Shitij Kapur;Robert B. Zipursky;Gary Remington

  • Negative Symptoms in Schizophrenia: Avolition and Occam's Razor

    George Foussias;Gary Remington;Gary Remington

  • Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics

    Claire H. Li;Robert E. Stratford;Nieves Velez de Mendizabal;Thomas I.F.H. Cremers

  • Direct Activation of the Ventral Striatum in Anticipation of Aversive Stimuli

    Jimmy Jensen;Anthony R McIntosh;Adrian P Crawley;David J Mikulis

  • A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.

    Shitij Kapur;Robert Zipursky;Corey Jones;C. S. Shammi

  • Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

    Shitij Kapur;Shitij Kapur;Gary Remington

  • 5-HT2 and D2 Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation

    Shitij Kapur;Robert B. Zipursky;Gary Remington;Corey Jones

  • Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.

    Shitij Kapur;Gary Remington

  • Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome:

    Tony Cohn;Denis Prud'homme;David Streiner;Homa Kameh

  • Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

    W Wolfgang Fleischhacker;Mariëlle Eerdekens;Keith Karcher;Gary Remington

  • Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.

    Simone Silvestri;Mary V. Seeman;Juan-Carlos Negrete;Sylvain Houle

  • The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study

    Shitij Kapur;Gary Remington;Robert B Zipursky;Alan A Wilson

  • Validation of a physical activity assessment tool for individuals with schizophrenia.

    Guy Faulkner;Tony Cohn;Tony Cohn;Gary Remington;Gary Remington

  • Increased stress-induced dopamine release in psychosis.

    Romina Mizrahi;Romina Mizrahi;Jean Addington;Pablo M. Rusjan;Ivonne Suridjan

  • High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

    Shitij Kapur;Gary Remington;Corey Jones;Alan Wilson

  • Interventions to Reduce Weight Gain in Schizophrenia

    Guy Faulkner;Tony Cohn;Gary Remington

Frequent Co-Authors

George Foussias
George Foussias Centre for Addiction and Mental Health
Ariel Graff-Guerrero
Ariel Graff-Guerrero Centre for Addiction and Mental Health
Shitij Kapur
Shitij Kapur King's College London
Aristotle N. Voineskos
Aristotle N. Voineskos Centre for Addiction and Mental Health
James L. Kennedy
James L. Kennedy Centre for Addiction and Mental Health
Robert B. Zipursky
Robert B. Zipursky University of Toronto
Guy Faulkner
Guy Faulkner University of British Columbia
Herbert Y. Meltzer
Herbert Y. Meltzer Northwestern University
Konstantine K. Zakzanis
Konstantine K. Zakzanis University of Toronto
Bruce G. Pollock
Bruce G. Pollock University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine or healthcare isn’t limited to becoming a doctor. There are many flexible, online options for advancing your career or changing fields in the US. For example, those looking to quickly advance nursing credentials might consider a 1 year dnp program online, which provides a fast track to a doctoral nursing degree.

Students seeking a faster pathway to nursing can explore a 9 month lpn program. This allows for a quicker entry into the nursing profession, meeting the growing demand for licensed practical nurses.

For those interested in mental health, psych np online programs offer a flexible way to specialize and support patients dealing with psychiatric challenges.

Not all healthcare careers require direct patient care. If you’re interested in hospital or clinic management, health administration degrees online provide a convenient route to leadership roles within the healthcare system.

By exploring these online pathways, students and professionals can enhance their careers in medicine and healthcare while balancing work and family commitments.

Best Scientists Citing Gary Remington

Trending Scientists

Recently Published Articles